Ptc Therapeutics (PTCT) Current Leases (2019 - 2026)

Ptc Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Current Leases fell 47.66% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 47.66% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, changed 0.0% from the prior year.
• Current Leases climbed to $6.0 million in Q1 2026 per PTCT's latest filing, from $3.0 million in the prior quarter.
• Across five years, Current Leases topped out at $14.6 million in Q1 2024 and bottomed at $1.8 million in Q1 2022.
• The 5-year median for Current Leases is $3.0 million (2023), against an average of $6.0 million.
• Across the five-year window, Current Leases jumped 441.65% in 2023 and sank 81.04% in 2025, its largest moves.
• Year by year, Current Leases stood at $9.4 million in 2022, then sank by 67.98% to $3.0 million in 2023, then changed by 0.0% to $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025, then soared by 100.0% to $6.0 million in 2026.
• Per Business Quant, the three latest PTCT Current Leases figures stand at $6.0 million (Q1 2026), $3.0 million (Q4 2025), and $2.7 million (Q3 2025).